151 related articles for article (PubMed ID: 38154274)
1. Ergosterol peroxide blocks HDV infection as a novel entry inhibitor by targeting human NTCP receptor.
Chiou WC; Lyu YS; Hsia TL; Chen JC; Lin LC; Chang MF; Hsu MS; Huang C
Biomed Pharmacother; 2024 Jan; 170():116077. PubMed ID: 38154274
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide.
He W; Ren B; Mao F; Jing Z; Li Y; Liu Y; Peng B; Yan H; Qi Y; Sun Y; Guo JT; Sui J; Wang F; Li W
PLoS Pathog; 2015 Apr; 11(4):e1004840. PubMed ID: 25902143
[TBL] [Abstract][Full Text] [Related]
3. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide.
Yan H; Peng B; Liu Y; Xu G; He W; Ren B; Jing Z; Sui J; Li W
J Virol; 2014 Mar; 88(6):3273-84. PubMed ID: 24390325
[TBL] [Abstract][Full Text] [Related]
4. Ergosterol peroxide inhibits HBV infection by inhibiting the binding of the pre-S1 domain of LHBsAg to NTCP.
Huang H; Huang HC; Chiou WC; Lin LC; Chen JC; Liu HK; Lai YH; Huang C
Antiviral Res; 2021 Nov; 195():105184. PubMed ID: 34627935
[TBL] [Abstract][Full Text] [Related]
5. Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.
Winer BY; Shirvani-Dastgerdi E; Bram Y; Sellau J; Low BE; Johnson H; Huang T; Hrebikova G; Heller B; Sharon Y; Giersch K; Gerges S; Seneca K; Pais MA; Frankel AS; Chiriboga L; Cullen J; Nahass RG; Lutgehetmann M; Toettcher JE; Wiles MV; Schwartz RE; Ploss A
Sci Transl Med; 2018 Jun; 10(447):. PubMed ID: 29950446
[TBL] [Abstract][Full Text] [Related]
6. Murine hepatocytes do not support persistence of Hepatitis D virus mono-infection in vivo.
Giersch K; Hermanussen L; Volz T; Kah J; Allweiss L; Casey J; Sureau C; Dandri M; Lütgehetmann M
Liver Int; 2021 Feb; 41(2):410-419. PubMed ID: 32997847
[TBL] [Abstract][Full Text] [Related]
7. Long-term
Lowjaga KAAT; Kirstgen M; Müller SF; Goldmann N; Lehmann F; Glebe D; Geyer J
Am J Physiol Gastrointest Liver Physiol; 2021 Jan; 320(1):G66-G80. PubMed ID: 33174454
[TBL] [Abstract][Full Text] [Related]
8. Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP.
Donkers JM; Zehnder B; van Westen GJP; Kwakkenbos MJ; IJzerman AP; Oude Elferink RPJ; Beuers U; Urban S; van de Graaf SFJ
Sci Rep; 2017 Nov; 7(1):15307. PubMed ID: 29127322
[TBL] [Abstract][Full Text] [Related]
9. Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP).
Veloso Alves Pereira I; Buchmann B; Sandmann L; Sprinzl K; Schlaphoff V; Döhner K; Vondran F; Sarrazin C; Manns MP; Pinto Marques Souza de Oliveira C; Sodeik B; Ciesek S; von Hahn T
PLoS One; 2015; 10(2):e0117152. PubMed ID: 25646622
[TBL] [Abstract][Full Text] [Related]
10. Modification of Three Amino Acids in Sodium Taurocholate Cotransporting Polypeptide Renders Mice Susceptible to Infection with Hepatitis D Virus In Vivo.
He W; Cao Z; Mao F; Ren B; Li Y; Li D; Li H; Peng B; Yan H; Qi Y; Sun Y; Wang F; Sui J; Li W
J Virol; 2016 Oct; 90(19):8866-74. PubMed ID: 27466423
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis delta virus RNA decline post-inoculation in human NTCP transgenic mice is biphasic.
Maya S; Hershkovich L; Cardozo-Ojeda EF; Shirvani-Dastgerdi E; Srinivas J; Shekhtman L; Uprichard SL; Berneshawi AR; Cafiero TR; Dahari H; Ploss A
mBio; 2023 Aug; 14(4):e0100823. PubMed ID: 37436080
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.
Ni Y; Lempp FA; Mehrle S; Nkongolo S; Kaufman C; Fälth M; Stindt J; Königer C; Nassal M; Kubitz R; Sültmann H; Urban S
Gastroenterology; 2014 Apr; 146(4):1070-83. PubMed ID: 24361467
[TBL] [Abstract][Full Text] [Related]
13. Sodium taurocholate cotransporting polypeptide is the limiting host factor of hepatitis B virus infection in macaque and pig hepatocytes.
Lempp FA; Wiedtke E; Qu B; Roques P; Chemin I; Vondran FWR; Le Grand R; Grimm D; Urban S
Hepatology; 2017 Sep; 66(3):703-716. PubMed ID: 28195359
[TBL] [Abstract][Full Text] [Related]
14. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide.
Yan H; Peng B; He W; Zhong G; Qi Y; Ren B; Gao Z; Jing Z; Song M; Xu G; Sui J; Li W
J Virol; 2013 Jul; 87(14):7977-91. PubMed ID: 23678176
[TBL] [Abstract][Full Text] [Related]
15. Woodchuck sodium taurocholate cotransporting polypeptide supports low-level hepatitis B and D virus entry.
Fu L; Hu H; Liu Y; Jing Z; Li W
Virology; 2017 May; 505():1-11. PubMed ID: 28213271
[TBL] [Abstract][Full Text] [Related]
16. IFITM3 Interacts with the HBV/HDV Receptor NTCP and Modulates Virus Entry and Infection.
Palatini M; Müller SF; Kirstgen M; Leiting S; Lehmann F; Soppa L; Goldmann N; Müller C; Lowjaga KAAT; Alber J; Ciarimboli G; Ziebuhr J; Glebe D; Geyer J
Viruses; 2022 Mar; 14(4):. PubMed ID: 35458456
[TBL] [Abstract][Full Text] [Related]
17. Sodium taurocholate cotransporting polypeptide acts as a receptor for hepatitis B and D virus.
Yan H; Li W
Dig Dis; 2015; 33(3):388-96. PubMed ID: 26045274
[TBL] [Abstract][Full Text] [Related]
18. Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications.
Li W; Urban S
J Hepatol; 2016 Apr; 64(1 Suppl):S32-S40. PubMed ID: 27084034
[TBL] [Abstract][Full Text] [Related]
19. Cell Culture Models for the Study of Hepatitis D Virus Entry and Infection.
Heuschkel MJ; Baumert TF; Verrier ER
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452397
[TBL] [Abstract][Full Text] [Related]
20. Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle.
Blanchet M; Sureau C; Labonté P
Antiviral Res; 2014 Jun; 106():111-5. PubMed ID: 24717262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
